Mark Davis is a technically trained business services professional focused on helping biotechnology companies make informed decisions related to their external manufacturing strategy and engagement. He holds a Master of Science in Organic Chemistry and MBA in International Business. Mark has supported Pharmaceutical and Biotechnology innovator programs across all modalities - small and large molecule, cell and gene therapies. He has unique direct experience in leading engagement negotiations for outsourced manufacturing with CAR-T, TCR, viral vector (including Lenti, Adenoviral, AAV), plasmid, mAB, protein, and CRISPR based therapies as examples. Mark’s direct experience with CMC related transaction and negotiations included full responsibility for transactions involving a combination of intellectual property (IP), development, and supply elements. As a member of Novartis’ Kymriah program from 2014-16, as well as supporting cell therapy business deals with two other top 15 pharmaceutical companies, he negotiated various agreements often requiring "green field" development of technologies specific to a program. Additionally, Mark has a track record of significant risk and cost reductions in many development to commercial phase programs through global scale supply chain development, including small molecules such as Novartis' Zykadia and Kisqali.